Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 502905520

Sigma Aldrich Fine Chemicals Biosciences Bleomycin ready made solut

Catalog No. 502905520
Encompass

Bleomycin (BLM) is a glycopeptide antibiotic consist of 2 main isomers BLM A2 and B2 obtained from Streptomyces verticillus. The main clinical application of Bleomycin is cancer treatment. Bleomycin causes oxidative degradation of RNA affecting G2 and M cell cycle phases. The anti-cancer mechanism of Bleomycin is mediated through iron chelation and generation of oxygen free radicals leading to DNA cleavage and ultimately to cell death. Bleomycin hydrolase the enzyme responsible for Bleomycin metabolism is normally present at low levels in the lungs. Therefore Bleomycin treatment may result in its accumulation in the lungs and can potentially cause lung injury due to lung cell death. The lung injury occurs through overproduction of reactive oxygen species causing pulmonary toxicity leading to fibrosis. The lung fibrosis by Bleomycin can be utilized for screening of antifibrotic agents.Bleomycin has several important applicationsBleomycin has been used to induce chronic lung d

Catalog No. 50-290-5520 Supplier Sigma Aldrich Fine Chemicals Biosciences Supplier No. B72161ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Bleomycin (BLM) is a glycopeptide antibiotic consist of 2 main isomers BLM A2 and B2 obtained from Streptomyces verticillus. The main clinical application of Bleomycin is cancer treatment. Bleomycin causes oxidative degradation of RNA affecting G2 and M cell cycle phases. The anti-cancer mechanism of Bleomycin is mediated through iron chelation and generation of oxygen free radicals leading to DNA cleavage and ultimately to cell death. Bleomycin hydrolase the enzyme responsible for Bleomycin metabolism is normally present at low levels in the lungs. Therefore Bleomycin treatment may result in its accumulation in the lungs and can potentially cause lung injury due to lung cell death. The lung injury occurs through overproduction of reactive oxygen species causing pulmonary toxicity leading to fibrosis. The lung fibrosis by Bleomycin can be utilized for screening of antifibrotic agents.Bleomycin has several important applicationsBleomycin has been used to induce chronic lung d

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.